| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2014/050 | ||
|---|---|---|---|
| Date of filing | 11/09/2014 | ||
| Notification of Application Published | 08/10/2014 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
MERCK SHARP & DOHME CORP. 126 East Lincoln Avenue Rahway Rahway New Jersey 07065-4607 UNITED STATES OF AMERICA |
||
| Patent Number | 0720599 | ||
| Title of Invention | HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | ||
| Date of Expiry of Patent | 13/09/2014 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Ezetimibe and rosuvastatin or pharmaceutically acceptable salts thereof, including rosuvastatin as a zinc salt | Market Authorisation | Ireland | Norway |
| Authorisation No | PA1470/004/001-003 | 13-9663-13-9665 | |
| Authorisation Date | 08/08/2014 | 24/07/2014 | |
| Identity of Product Authorised | Viazet 10mg/10mg hard capsule, Viazet 20mg/10mg hard capsule, Viazet 40mg/10mg hard capsule | Viazet 10mg/10mg hard capsule, Viazet 20mg/10mg hard capsule, Viazet 40mg/10mg hard capsule | |
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||
| Renewal Fees | |||
| 15/09/2014 | Request for grant a Supplementary Protection Certificate filed on 11/09/2014, numbered 2014/050. | ||
| 22/05/2017 | Request for grant of Supplementary Protection Certification No. 2014/050 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
| 17/11/2017 | Controller notified on 9 November 2017 of an appeal to the High Court on 18 October 2017 by Merck, Sharp & Dohme Corp. against the decision of the Controller to reject SPC No. 2014/050. | ||
| 28/02/2018 | Controller notified on 16 February 2018 of decision of the Plaintiff, Merck Sharp & Dohme Corp. to discontinue their legal proceedings at the High Court. | ||
| 24/03/2021 | Written grounds of decision issued on 3 August 2017. | ||